# AUTHOR INDEX

(P = proceedings)


ABEL, S. M. & BACK, D. J. Inhibition of human liver cortisol δ4-reductase and cortisol 6β-hydroxylase *in vitro*, 160P
ABOSEHMAH, A. Z. M., YORK, P., WONG, V., BRAMLEY, P. N., BURGUL, R., LOSOWSKY, M. & CHRYSTYN, H. Improved bioavailability and efficacy of a spironolactone betacyclodextrin formulation, 488P
ACTON, G. *see* EAGLE, S.
ACTON, G. *see* ROSE, J.
ADGEY, A. A. J. *see* HERITY, N. A.
AHERN, M. J. *see* HAYBALL, P. J.
AHMED, J. H., GODDEN, J., MEREDITH, P. A. & ELLIOTT, H. L. R-verapamil: pharmacokinetics and effects on PR interval, blood pressure and heart rate, 93
AKKILA, J. *see* SUNDBERG, S.
ALLARD, G. *see* BEAULAC-BAILLARGEON
ALLARD, S., CHRYSTYN, H., ROBERTS, B. & FEELY, M. Refinement of the technique of using low-dose phenobarbitone when assessing compliance with warfarin, 503P
ALLEN, J. D. *see* HERITY, N. A.
ALLEN, S. P. *see* DASHWOOD, M. R.
ALLOTT, R. *see* PIRMOHAMED, M.
AMBROSE, J. *see* TRAUB, M.
ANDERSON, R. M. & WALLACE, H. M. Oxidant-induced DNA damage in HT115 cells, 150P
ANDERSON, T., MINERS, J. O., TASSANEEYAKUL, W., TASSANEEYAKUL, W., VERONESE, M. E., MEYER, U. A. & BIRKETT, D. J. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism, 521
ANDERSSON, P., BRATTSAND, R., DAHLSTROM, K. & EDSBACKER, S. Oral availability of fluticasone propionate, 135
ARROYO, J. F. *see* WALKER, J. S.
AUDEBERT, C. *see* BLIN, O.
AYRTON, J. *see* SHENOY, E. V. B.
AZAM, A. *see* VANCHEESWARAN, R.

BACHMANN, K. A., SULLIVAN, T. J., JAUREGUI, L., REESE, J. H., MILLER, K. & LEVINE, L. Absence of an inhibitory effect of omeprazole and nizatidine on phenytoin disposition, a marker of CYP2C activity, 380
BACK, D. *see* BARRY, M.
BACK, D. J. *see* ABEL, S.M.
BACK, D. J. *see* EAGLING, V.
BACK, D. J. *see* HOWE, J. L.
BACK, D. J. *see* ISMAIL, S.
BACK, D. J. *see* VEAL, G.J.
BAINBRIDGE, A. D., MACFADYEN, R. J., STARK, S., LEES, K. R. & REID, J. L. The antihypertensive efficacy and tolerability of a low dose combination of ramipril and felodipine ER in mild to moderate essential hypertension, 323
BAINBRIDGE, A. D., MEREDITH, P. A. & ELLIOTT, H. L. A clinical pharmacological assessment of doxazosin and enalapril in combination, 599
BALDERSON, D. J. *see* ROBERTS, D. A.
BALDERSON, D. J., ROBERTS, D. A., DEAKIN, J. W. F. & OWEN, F. The abundance of 5-$HT_{1A}$ receptor mRNA in post-mortem brain samples from controls and schizophrenics, 490P
BALL, C. J., MCCLAREN, P. M. & MORRISON, P. J. The personality structure of 'normal' volunteers, 369
BARBE, P., GALITZKY, J., RIVIERE, D., SENARD, J. M., LAFONTAN, M., GARRIGUES, M. & BERLAN, M. Effects of physiological and pharmacological variation of sympathetic nervous system activity on plasma non-esterified fatty acid concentrations in man, 25
BARHAM, H. A., LENNARD, M. S., TUCKER, G. T. & WOODS, H. F. The activities of cytochrome P450 isoenzymes in the female DA rat, 154P
BARNARD, S., MCGOLDRICK, T. A., PARK, B. K. & HAWKSWORTH, G. M. The effect of fluorine substitution on the hepatotoxicity of paracetamol *in vitro*, 147P
BARR, C. S., LANG, C. C. & STRUTHERS, A. D. A comparison of the effects of low and high dose captopril on the natriuretic response to atrial natriuretic factor in normal man, 142P
BARRETT, D. A., SIMPSON, J., RUTTER, N., KURIHARA-BERGSTROM, T., SHAW, P. N. & DAVIS, S. S. The pharmacokinetics and physiological effects of buprenorphine infusion in premature neonates, 215
BARRY, M. *see* HOWE, J. L.
BARRY, M., BACK, D., ORMESHER, S., BEECHING, N. & NYE, F. Metabolism of didanosine (ddI) by erythrocytes: pharmacokinetics implications, 87
BARRY M., HOWE, J., BACK, D., BRECKENRIDGE, A., BRETTLE, R., MITCHELL, R., BEECHING, N. J. & NYE, F. J. The effects of indomethacin and naproxin on zidovudine pharmacokinetics, 82
BARTOLI, A. *see* GATTI, G.
BARTOLI, A. *see* TARTARA, A.
BATH, P. *see* BAUDOIN, S. V.
BAUDOUIN, S. V., BATH, P., MARTIN, J. F., DU BOIS, R. & EVANS, T. W. L-Arginine infusion has no effect on systemic haemodynamics in normal volunteers, or systemic and pulmonary haemodynamics in patients with elevated pulmonary vascular resistance, 45
BAUER, K. G., KAIK, B., SERTL, K. & KAIK, G. A. Studies on the bronchodilator, tremorogenic, cardiovascular and hypokalaemic effects of fenoterol dry powder in asthma, 285
BEARDON, P. H. G. *see* MACDONALD, T. M.
BEAULAC-BAILLARGEON & ALLARD, G. Distribution of indomethacin in human milk and estimation of its milk to plasma ratio *in vitro*, 413
BEAULIEU, M., NADEAU, A., LACOURCIERE, Y. & CLEROUX, J. Post-exercise reduction in blood pressure in hypertensive subjects: effects of angiotensin converting enzyme inhibition, 331
BEECHING, N. *see* BARRY, M.
BEECHING, N. *see* HOWE, J. L.
BEECHING, N. J. *see* BARRY, M.
BELL, G. D. *see* SMITH, M. R.
BELL, G. M. *see* COSTIGAN, M. G.
BELL, J. A. *see* STEWART, V. C.
BELL, N. *see* NUGENT, A.-M.
BELZ, G. G. *see* DE MEY, C.
BENJAMIN, N. *see* TANG, Y. S.
BENNETT, P. *see* BRIDGMAN, K.
BENNETT, P. N., OLIVER, S. & NOTARIANI, L. J. Age, acetylator status and xanthine oxidase activity, 148P
BENOWITZ, N. L. *see* GUPTA, S. K.
BERLAN, M. *see* BARBE, P.
BERRY, D. J. *see* LEAKEY, T. E. B.
BIRKETT, C. D. *see* LAMB, R. J.
BINNIE, D. J. *see* ANDERSON, T.
BIRMINGHAM, A. T. *see* JAMES, M. J.
BIRNBOECK, H. *see* WEBER, C.
BJORNSSON, T. D. *see* SCHWARTZ, J. I.
BLACK, C. M. *see* VANCHEESWARAN, R.
BLACKLAW, J. *see* MCKEE, P. J. W.
BLIN, O., MESTRE, D., PAUT, O., VERCHER, J. L. & AUDEBERT, C. GABA-ergic control of visual perception in healthy volunteers: effects of midazolam, a benzodiazepine, on spatio-temporal contrast sensitivity, 117
BLOUIN, R. A. *see* ISRAEL, B. C.
BOCCHETTA, A. *see* MARTINELLI, V.

BOCHNER, F. *see* HAYBALL, P. J.
BOLDT, J., KNOTHE, CH., ZICKMANN, B., SCHINDLER, E., STERTMANN, W. A. & HEMPLEMANN, G. Circulatory effects of the PDE-inhibitors piroximone and enoximone, 309
BONE, J. M. *see* COSTIGAN, M. G.
BONFILS, C. *see* CURI-PEDROSA, R.
BOPP, B. A. *see* HUSSEIN, Z.
BORG-COSTANZI, J. M. *see* DIXON, J. S.
BOULOUX, P. M. G. *see* WRIGHT, D. M.
BOUSTEAD, C. *see* CHOLERTON, S.
BOWERS, G. D. *see* SHENOY, E. V. B.
BRAMLEY, P. N. *see* ABOSEHMAH, A. Z. M.
BRATTSAND, R. *see* ANDERSSON, P.
BRECKENRIDGE, A. *see* BARRY, M.
BRECKENRIDGE, A. M. *see* HOWE, J. L.
BRECKENRIDGE, A. M. *see* PIRMOHAMED, M.
BREIMER, D. D. *see* DE BOER, A.
BRENNAN, G. M., MCDOWELL, I. F. W., MCENENY, J., NICHOLLS, D. P. & JOHNSTON G. D. The effect of antioxidant treatment on LDL oxidation and endothelial responses in type II hypercholesterolaemia, 175P
BRETTLE, R. *see* BARRY, M.
BRIDGMAN, K., BENNETT, P., DARBY, R., DUNNETT, S., FAWCETT, H., LONGHSHAW, R., SHEPHARD, A. & SMITH, C. A feasibility study on hospital postmarketing surveillance, 492P
BRODIE, M. J. *see* LARKIN, J. G.
BRODIE, M. J. *see* MCKEE, P. J. W.
BROOKHUIS, K. A., DE VRIES, G. & DE WAARD, Acute and subchronic effects of the $H_1$-histamine receptor antagonist ebastine in 10, 20 and 30 mg dose, and triprolidine 10 mg on car driving performance, 67
BROOM, C. *see* EAGLE, S.
BROOM, C. *see* PUE, M. A.
BRØSEN, K., SKJELBO, E. & FLACHS, H. Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark, 105
BROWN, F. T., JAPPY, B. M. & PETRIE, J. C. An assessment of the acceptability and utilisation of a joint hospital/general practice formulary, 179P
BRUNELLE, R. L., GOLDSTEIN, D. J., GEORGE, R. E. & ZIMMERMAN, D. M. Intramuscular picenadol in patients with postoperative pain, 351
BUIST, A., NORMAN, T. R. & DENNERSTEIN, L. Mianserin in breast milk, 133
BURGUL, R. *see* ABOSEHMAH, A. Z. M.
BURKE, M. D. *see* MCKAY, J. A.
BURKE, M. D. *see* WANOGHO, E.
BURKE, M. D. *see* WEAVER, R. J.
BUTZER, R. *see* DE MEY, C.
BYE, A. The oral systemic availability of fluticasone propionate in man—preliminary data, 136
BYGATE, E. *see* PUE, M. A.

CAMERON, D. W. *see* GALLICANO, K.
CAMPBELL, N. R. C., WICKERT, W. A. & SHUMAK, S. L. Frusemide causes acute increases in lipid concentrations, 607
CAREY, C., CLARK, M., LOPEZ-GIL, J. A. & VERE, D. W. The basis of the histamine assay in human skin: II wheal formation, 39
CARRUTHERS, S. G. *see* POLLAK, P. T.
CARSWELL, A. *see* MCKEE, P. J. W.
CASTLEDEN, C. M. *see* ELLIOTT, R. A.
CHAN, K. & JONES, D. M. An h.p.l.c. assay for flumezanil, midazolam and their metabolites in plasma and urine of paediatric patients, 168P
CHAN, K., LO, A. C. T. & YEUNG, J. H. K. The effect of Danshen (*Salvia miltiorrhiza*) on the plasma concentrations of R- and S-warfarin in rats, 147P
CHAPELSKY, M. *see* EAGLE, S.
CHARMAN, S. A. *see* CHARMAN, W. N.
CHARMAN, W. N., CHARMAN, S. A., MONKHOUSE, D. C., FRISBEE, S. E., LOCKHART, E. A., WEISMAN, S. & FITZGERALD, G. A. Biopharmaceutical characterisation of a low-dose (75 mg) controlled-release aspirin formulation, 470
CHESTERMAN, L. P. *see* LAMB, R. J.
CHIJIOKE, C. P. Effect of tetracycline on human sperm motility and fertilizing ability, 497P
CHIN, J. P. F., HURLSTON, R. M. & DART, A. M. Inhibition of prostaglandin synthesis does not affect contractile responses to noradrenaline, serotonin, angiotensin II nor endothelin-1 in human forearm isolated veins, 303
CHO, A. K. *see* TUCKER, G. T.
CHOLERTON, S. & IDLE, J. R. The influence of water diuresis on the urinary excretion of 7-hydroxycoumarin, 180P
CHOLERTON, S., BOUSTEAD, C., TABER, H. & IDLE, J. R. A population study of the cardiovascular effects of an oral dose of nicotine in non-smokers, 173P
CHOONARA, I. A. *see* PIRMOHAMED, M.
CHOY, A. M., DARBAR, D., LANG, C. C., PRINGLE, T. H., MCMURDO, M., RODRIGUES, J. & STRUTHERS, A. D. Attitudes of physicians in the treatment of congestive heart failure in the elderly, 174P
CHOY, A. M. J. *see* LANG, C. C.
CHRYSTYN, A. *see* ABOSEHMAH, A. Z. M.
CHRYSTYN, H. *see* ALLARD, S.
CHRYSTYN, H. *see* CORLETT, S. A.
CHU, T. *see* TUCKER, G. T.
CLARK, M. *see* CAREY, C.
CLEROUX, J. *see* BEAULIEU, M.
COCKSHOTT, I. D., SOTANIEMI, E. A., COOPER, K. J. & JONES, D. C. The pharmacokinetics of Casodex enantiomers in subjects with impaired liver function, 339
COHEN, A. F. *see* DE BOER, A.
COHEN, A. F. *see* STIEKMA, J. C. J.
COHEN, A. F. *see* VAN STEVENINCK, A. L.
COHEN, A. F. *see* TRISCARI, J.
COLLINS, G. *see* EKINS, S.
COOK, A. J., GREALLY, P., SAMPSON, A. P., PIPER, P. J. & PRICE, J. F. The influence of atopy on urinary $LTE_4$ and lung function in cystic fibrosis children, 494P
COOPER, A. E., GRAY, A., RICHMOND, H., MOODY, G., JOHN, S., STEWART, F. & LOGAN, C. Characterisation of liver enzyme induction following administration of tripradane by inhalation, 155P
COOPER, K. J. *see* COCKSHOTT, I. D.
CORLETT, S. A., SELBY, P. & CHRYSTYN, H. Pharmacokinetics of ifosfamide and its enantiomers when given by continuous infusion: a preliminary investigation, 488P
COSTELLO, J. F. *see* MILNE, A. A. Y.
COSTIGAN, M. G., YAQOOB, M., MCCLELLAND, P., BELL, G. M., BONE, J. M. & LINDUP, W. E. Plasma concentration of a furan dicarboxylic acid and the effect of chronic renal failure and kidney transplant, 164P
COURNOT, A. *see* FLOUVAT, B.
COVILLE, P. F. *see* WANWIMOLRUK, S.
CURI-PEDROSA, R., PICHARD, L., BONFILS, C., JACQZ-AIGRAIN, E. & MAUREL, P. Major implication of cytochrome P4503A in the oxidative metabolism of the antisecretory drugs omeprazole and lansoprazole in human liver microsomes and hepatocytes, 156P
CUSAK, B. J. *see* LOI, C.-M.
CUTLER, D. J. *see* MCLACHLAN, A. J.

DAGG, K. D. *see* LIPWORTH, B. J.
DAHLSTROM, K. *see* ANDERSSON, P.
DAMASCHKE, A. *see* DAMMANN, H. G.
DAMMANN, H. G., SIMON-SCHULTZ, J., STEINHOFF, I., DAMASCHKE, A., SCHMOLDT, A., SALLOWSKY, E. & SCHULTZ, M. Differential effects of misoprostol and ranitidine on the pharmacokinetics

of diclofenac and gastrointestinal symptoms, 345
DANHOF, M. *see* VAN STEVENINCK, A. L.
DANIEL, M. J. *see* SHENOY, E. V. B.
DANIELS, S. *see* PUE, M. A.
DARBAR, D. *see* CHOY, A. M.
DARBY, R. *see* BRIDGMAN, K.
DART, A. M. *see* CHIN, J. P. F.
DASHWOOD, M. R. *see* VANCHEESWARAN, R.
DASHWOOD, M. R., MUDDLE, J. R., LUU, T. N. & ALLEN, S. P. Regional variations in [$^{125}$I]-ET-1 binding to the atherosclerotic human coronary artery revealed by the novel $ET_A$ antagonist FR 139317, 490P
DAVEY, P., HUDSON, S., RIDGWAY, G. & REEVES, D. A survey of undergraduate and continuing medical education about antimicrobial chemotherapy in the United Kingdom, 511
DAVIES, D. L. Do diuretics cause magnesium deficiency?, 1
DAVIS, S. S. *see* BARRETT, D. A.
DAWKINS, K. D. *see* DONALDSON, K. M.
DAY, R. O. *see* MCLACHLAN, A. J.
DAY, R. O. *see* WALKER, J. S.
DE BOER, A. & WALLER, P. C. Frequency of adverse drug reactions, 88
DE BOER, A., KLUFT, C., KASPER, F. J., KROON, J. M., SCHOEMAKER, H. C., BREIMER, D. D., SOONS, P. A. & COHEN, A. F. Interaction study between nifedipine and recombinant tissue-type activator in healthy subjects, 99
DE MEY, C. *see* EAGLE, S.
DE MEY, C., ENTERLING, D. & MEINEKE, I. Cardiovascular effects of eating, atenolol and their interaction: $\beta_1$-adrenergic modulation does not play a predominant role in the genesis of postprandial effects, 427
DE MEY, C., MATTHEWS, J., BUTZER, R., SCHROETER, V. & BELZ, G. G. Agreement and reproducibility of the estimates of cardiovascular function by impedance cardiography and M-mode echocardiography in healthy subjects, 88
DE VRIES, G. *see* BROOKHUIS, K. A.
DE WAARD, D. *see* BROOKHUIS, K. A.
DEAKIN, J. W. F. *see* BALDERSON, D. J.
DEAKIN, J. W. F. *see* ROBERTS, D. A.
DEAKIN, J. W. F. *see* SIMPSON, M. D. C.
DECOLIN, D. *see* LAURENT-KENESI, M.-A.
DEHOORNE-SMITH, M. *see* DUCHARME, M. P.
DEL-PINO, M. *see* LE QUAN SANG
DEL ZOMPO, M. *see* MARTINELLI, V.
DELHOTAL-LANDES, B. *see* FLOUVAT, B.
DELLATOLAS, F. *see* FLOUVAT, B.
DENNERSTEIN, L. *see* BUIST, A.
DEVAULT, A. *see* TRISCARI, J.
DEVYNCK, M.-A. *see* LE QUAN SANG
DICKINS, M. *see* WEAVER, R. J.
DIRNHUBER, M. *see* RASHID, J.
DIXON, J. S., BORG-COSTANZI, J. M., LANGLEY, S. J., LACEY, L. F. & TOON, S. The effect of renal function on the pharmacokinetics of ranitidine, 178P
DONALDSON, K. M., DAWKINS, K. D. & WALLER, D. G. A comparison of the acute haemodynamic effects of nisoldipine and nifedipine during treatment with atenolol in patients with coronary artery disease, 315
DU BOIS, R. *see* BAUDOUIN, S. V.
DUCHARME, M. P., PROVENZANO, R., DEHOORNE-SMITH, M. & EDWARDS, D. J. Trough concentrations of cyclosporine in blood following administration with grapefruit juice, 457
DUCHE, J.-C. *see* HERVE, F.
DUDDY, E. *see* HERITY, N. A.
DUNCAN, I. *see* MACDONALD, T. M.
DUNCAN, J. N. *see* MARTIN, I. J.
DUNNETT, S. *see* BRIDGMAN, K.
DUPONT, A. G. *see* VERCRUYSSE, J.

EAGLE, S., GILL, C., ACTON, G., HORTON, J., WRITER, D., MEINEKE, I., DE MEY, C. & BROOM, C. Relative bioavailability of a new micronised formulation of halofantrine, 176P
EAGLE, S., GILL, C., CHAPELSKY, M., SWAGZDIS, J., PUE, M. & BROOM, C. Pharmacokinetics and clinical tolerability of the reversible proton pump inhibitor SK&F 96967, 175P
EAGLING, V. & BACK, D. J. The reduction of zidovudine to the toxic catabolite 3′-amino 3′ deoxy-thymidine (AMT) *in vitro*, 161P
EDSBACKER, S. *see* ANDERSSON, P.
EDWARDS, D. J. *see* DUCHARME, M. P.
EDWARDS, G. *see* ISMAIL, S.
EDWARDS, G. *see* SZWANDT, I. S. F.
EKINS, S., COLLINS, G., NEWLANDS, A. J., WILLIAMS, J. A., MARCHANT, N. C., LUCAS, C. & HAWKSWORTH, G. M. The role of cytochrome P4503A in the metabolism of the vinca alkaloid α-aminophosphonate derivative S12363 by human liver microsomes, 165P
ELLIOTT, H. L. *see* AHMED, J. H.
ELLIOTT, H. L. *see* BAINBRIDGE, A. D.
ELLIOTT, H. L. *see* MACDONALD, N. J.
ELLIOTT, H. L. *see* UEDA, S.
ELLIOTT, R. A. & CASTLEDEN, C. M. Nerve mediated relaxation in human detrusor muscle, 479
ELLIS, S. W. *see* ROWLAND, K.
ELLIS, S. W. *see* TUCKER, G. T.
ENTERLING, D. *see* DE MEY, C.
ERICSSON, H. *see* RANE, A.
EVANS, H. M. *see* LAMB, R. J.
EVANS, T. W. *see* BAUDOUIN, S. V.
EWEN, S. W. B. *see* MCKAY, J. A.

FAWCETT, H. *see* BRIDGMAN, K.
FEELY, J. Drug utilization and clinical pharmacology Report on British Pharmacological Society Symposium at Trinity College Dublin on Thursday 9th July 1992, 483
FEELY, M. *see* ALLARD, S.
FERNANDES, M. H. & SOARES-DA-SILVA, P. Aromatic L-amino acid decarboxylase and type A and B monoamine oxidase activity in renal tissues of developing dogs, 152P
FERNANDES, M. H. *see* VIEIRA-COELHO, M. A.
FIGGE, C. *see* KOLVENBACH, R.
FISET, C., PHILIPPON, F., GILBERT, M. & TURGEON, J. Stereoselective disposition of (±)-sotalol at steady-state conditions, 75
FITZGERALD, G. A. *see* CHARMAN, W. N.
FLACHS, H. *see* BRØSEN, K.
FLOUVAT, B., DELHOTAL-LANDES, B., COURNOT, A. & DELLATOLAS, F. Single and multiple dose pharmacokinetics of lansoprazole in elderly subjects, 469
FLOUVAT, B., DELHOTAL-LANDES, B., COURNOT, A., DELLATOLAS, F. & RECHERCHE, T. Single and multiple dose pharmacokinetics of lansoprazole in elderly subjects, 467
FOWLER, G. *see* LYONS, D.
FREESTONE, S. *see* LI KAM WA, T. C.
FRISBEE, S. E. *see* CHARMAN, W. N.
FUNCK-BRENTANO, C. *see* LAURENT-KENESI, M.-A.

GALIMBERTI, C. A. *see* TARTARA, A.
GALITZKY, J. *see* BARBE, P.
GALLICANO, K., SAHAI, J., ORMSBY, E., CAMERON, D. W., PAKUTS, A. & MCGILIVRAY, I. Pharmacokinetics of zidovudine after the initial single dose and during chronic-dose therapy in HIV-infected patients, 128
GARRIGUES, M. *see* BARBE, P.
GATTI, G., BARTOLI, A., MARCHISELLI, R., MICHELUCCI, R., TASSINARI, C. A., PISANI, F., ZACCARA, G., TIMMINGS, P., RICHENS, A. & PERUCCA, E. Vigabatrin-induced decrease in serum phenytoin concentration

does not involve a change in phenytoin bioavailability, 603
GATTI, G. *see* TARTARA, A.
GEORGE, C. F. *see* RASHID, J.
GEORGE, R. E. *see* BRUNELLE, R. L.
GERRARD, L., WHEELDON, N. M. & MCDEVITT, D. G. Effects of combined atenolol and nifedipine administration on psychomotor performance in man, 502P
GILBERT, M. *see* FISET, C.
GILL, C. *see* EAGLE, S.
GILLESPIE, J. S. *see* ODBER, J.
GILLHAM, R. A. *see* MCKEE, P. J. W.
GODDEN, J. *see* AHMED, J. H.
GODEHARDT, E. *see* KOLVENBACH, R.
GOLDBERG, A. *see* ODBER, J.
GOLDSTEIN, D. J. *see* BRUNELLE, R. L.
GOMAS, E. *see* HERVE, F.
GORDIN, A. *see* SUNDBERG, S.
GORSLINE, J. *see* GUPTA, S. K.
GRAINGER, A. M. *see* KILGOUR-CHRISTIE, J.
GRAM, L. F. *see* ROSHOLM, J.-U.
GRANNEMAN, G. R. *see* HUSSEIN, Z.
GRANT, M. H. *see* MACEWEN, E.
GRANT, M. H., RODGERS, E. H. & LI, S.-J. Mitoxantrone cytotoxicity is enhanced by 1,2-benzanthracene treatment of MCF8 cells, 162P
GRAY, A. *see* COOPER, A. E.
GREALLY, P. *see* COOK, A. J.
GRIFFITHS, A. *see* RICHENS, A.
GROSSMAN, A. *see* WRIGHT, D. M.
GUIMARAES, J. T. & SOARES-DA-SILVA, P. Effect of selective monoamine oxidase inhibition by Ro 41-1049 and Ro 19-6327 on the deamination of dopamine in isolated tubular epithelial cells of the rat kidney, 151P
GUPTA, S. K., BENOWITZ, N. L., JACOB III, P., ROLF, C. N. & GORSLINE, J. Bioavailability and absorption kinetics of nicotine following application of a transdermal system, 221
GUY, S. *see* THAM, T. C. K.
GUZELHAN, C. *see* HARTMANN, D.

HAHN, G. *see* WEBER-GRANDKE, H.
HALE, J. P. *see* LENNARD, L.
HALLAS, J. *see* ROSHOLM, J.-U.
HAMLEY, J. *see* MCMILLAN, T.
HANKEY, C. R. *see* SUMMERBELL, J.
HANSEN, L. J. *see* ROSHOLM, J.-U.
HANSSON, T. *see* RANE, A.
HARRISON, A. C., JEWELL, H., MAGGS, J. L. & PARK, B. K. Characterisation of a glucuronide of hydroxychloroquine, 11P
HARRISS, D. R. *see* JAMES, M. J.
HARTMANN, D., HUSSAIN, Y., GUZELHAN, C. & ODINK, J. Effect on dietary fat absorption of orlistat, administered at different times relative to meal intake, 266
HAWKSWORTH, G. *see* BARNARD, S.
HAWKSWORTH, G. *see* JONES, B. C.
HAWKSWORTH, G. M. *see* EKINS, S.
HAWKSWORTH, G. M. *see* STEWART, V. C.
HAWKSWORTH, G. M. *see* TANG, Y. S.
HAYBALL, P. J., NATION, R. L., BOCHNER, F., SANSOM, L. N., AHERN, M. J. & SMITH, M. D. The influence of renal function on the enantioselective pharmacokinetics and pharmacodynamics of ketoprofen in patients with rheumatoid arthritis, 185
HAYNES, W. G. *see* THOMSON, M.
HELSBY, N. A. *see* ISMAIL, S.
HEMPELMANN, G. *see* BOLDT, J.
HENDERSON, C. *see* RANE, A.
HENRY, J. A. *see* MINTON, N. A.
HERITY, N. *see* THAM, T. C. K.
HERITY, N. A., DUDDY, E., ALLEN, J. D., SILKE, B. & ADGEY, A. A. J. How does inhibition of nitric oxide synthesis cause a fall in cardiac output?, 181P
HERVE, F., GOMAS, E., DUCHE, J.-C. & TILLEMENT, J.-P. Evidence for differences in the binding of drugs to the main genetic variants of human $\alpha_1$-acid glycoprotein, 241
HERXHEIMER, A. Glyceryl trinitrate, flatus and defaecation, 481
HERXHEIMER, A. Systematic reviews of randomised controlled trials: important for clinical pharmacologists, 507
HILL, S. J. *see* JAMES, M. J.
HIRATSUKA, A. *see* TUCKER, G. T.
HOGAN, D. L. *see* HUSSEIN, Z.
HOLBROOK, J. & POSNER, J. The effect of *N*-methyl nalorphine on opiate-induced delay in upper gastrointestinal transit in healthy volunteers, 169P
HORNE, V. *see* JONES, B. C.
HORTON, J. *see* EAGLE, S.
HOWE, J. *see* BARRY, M.
HOWE, J. L., BARRY, M., BACK, D. J., SWART, A. M., BRECKENRIDGE, A. M., WELLER, I. V. D., BEECHING, N. & NYE, F. Zidovudine elimination in HIV-positive patients with and without zidovudine bone marrow suppression, 146P
HOWIE, C. A. *see* MACDONALD, N. J.
HOWIE, C. A. *see* UEDA, S.
HSIEH, J. Y. *see* SCHWARTZ, J. I.
HUDSON, S. *see* DAVEY, P.
HUGHES, D. M. *see* MACDONALD, N. J.
HURLSTON, R. M. *see* CHIN, J. P. F.
HUSEYIN, T. S. *see* MINTON, N. A.
HUSSAIN, Y. *see* HARTMANN, D.
HUSSEIN, Z., GRANNEMAN, G. R., MUKHERJEE, D., SAMARA, E., HOGAN, D. L., KOSS, M. A. & ISENBERG, J. I. Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole, 391
HUSSEIN, Z., MULFORD, D. J., BOPP, B. A. & GRANNEMAN, G. R. Stereoselective pharmacokinetics of pazinaclone, a new non-benzodiazepine anxiolytic, and its active metabolite in healthy volunteers, 357

IDLE, J. R. *see* CHOLERTON, S.
ILLI, A. *see* SUNDBERG, S.
INGRAM, C. G. *see* NEWNHAM, D. M.
ISENBERG, J. I. *see* HUSSEIN, Z.
ISMAIL, S., HELSBY, N. A., BACK, D. J. & EDWARDS, G. The effect of malaria infection on the conjugation of paracetamol in the rat isolated perfused liver, 157P
ISRAEL, B. C., BLOUIN, R. A., MCINTYRE, W. & SHEDLOFSKY, S. I. Effects of interferon-α monotherapy on hepatic drug metabolism in cancer patients, 229

JACKSON, P. R. *see* ROSTAMI HODJEGAN, A.
JACKSON, S. H. D. *see* KALRA, L.
JACKSON, S. H. D. *see* KINIRONS, M. T.
JACOB III, P. *see* GUPTA, S. K.
JACQZ-AIGRAIN, E. *see* CURI-PEDROSA, R.
JAILLON, P. *see* LAURENT-KENESI, M.-A.
JAMES, M. J., HARRISS, D. R., BIRMINGHAM, A. T. & HILL, S. J. Significance of atropine concentration for the incidence of tetrodotoxin-resistant relaxations of human detrusor strips, 480
JAPPY, B. M. *see* BROWN, F. T.
JARVINEN, A. O. *see* ROBERTS, G. W.
JAUREGUI, L. *see* BACHMANN, K. A.
JEWELL, H. *see* HARRISON, A. C.
JOHN, S. *see* COOPER, A. E.
JOHNSTON, G. D. *see* BRENNAN, G. M.
JOHNSTON, N. R. *see* LI KAM WA, T. C.
JONES, B. C., HAWKSWORTH, G., HORNE, V., NEWLANDS, A., TUTE, M. & SMITH, D. A. Putative action site model for CYP2C9 (tolbutamide hydroxylase), 143P
JONES, D. C. *see* COCKSHOTT, I. D.
JONES, D. M. *see* CHAN, K.
JONES, D. M. *see* RICHENS, A.
JONES, J. G. *see* SMITH, M. R.

KAIK, B. *see* BAUER, K. G.
KAIK, G. A. *see* BAUER, K. G.
KALRA, L., JACKSON, S. H. D. & SWIFT, C. G. Assessment of changes in psychomotor performance of elderly subjects, 383
KALRA, L. *see* KINIRONS, M. T.
KAMALI, F., THOMAS, S. H. L. & RAWLINS, M. D. Constraints on the

use of saliva phenytoin concentrations for the determination of its pharmacokinetics, 505P
KASPER, F. J. *see* DE BOER, A.
KEEN, M. *see* KEY, B. J.
KEENE, O. N. *see* KEMPSFORD, R. D.
KEMPSFORD, R. D., LACEY, L. F., KEENE, O. N. & THOMAS, M. The safety, tolerability and pharmacokinetics of subcutaneous GR85548, a novel 5-$HT_1$-receptor agonist for the treatment of migraine, 170P
KERANEN, T. *see* SUNDBERG, S.
KEY, B. J., WILKES, M. P. & KEEN, M. Reduced responsiveness to glyceryl trinitrate following antihypertensive treatment with nifedipine in man, 499P
KHAN, S., ROBERTS, P. & SKETT, P. The effect of insulin and glucocorticoids on the maintenance of steroid metabolising activity in rat hepatocytes, 153P
KILGOUR-CHRISTIE, J., GRAINGER, A. M. & WATT, A. H. A study of the completeness and accuracy of computer-held data routinely recorded at a hypertension clinic, 173P
KING, L. J. *see* MARTIN, I. J.
KINIRONS, M. T., JACKSON, S. H. D., KALRA, L., TREVIT, R. T. & SWIFT, C. G. Computerised psychomotor performance testing: a comparative study of the single dose pharmacodynamics of minaprine and amitriptyline in young and elderly subjects, 376
KITTERINGHAM, N. R. *see* PIRMOHAMED, M.
KLEINBLOESEM, C. H. *see* WEBER, C.
KLUFT, C. *see* DE BOER, A.
KNOTHE, CH. *see* BOLDT, J.
KNOTT, S. *see* LAMB, R. J.
KOBRIN, I. *see* WEBER, C.
KOLVENBACH, R., FIGGE, C., GODEHARDT, E. & SANDMANN, W. Adenosine agonists and global cerebral ischaemia, 134
KOSS, M. A. *see* HUSSEIN, Z.
KRISHNA, S., TER KUILE, F., SUPANARANOND, W., PUKRITTAYAKAMEE, S., TEJA-ISAVADHARM, P., KYLE, D. & WHITE, N. J. Pharmacokinetics, efficacy and toxicity of parenteral halofantrine in uncomplicated malaria, 585
KROON, J. M. *see* DE BOER, A.
KURIHARA-BERGSTROM, T. *see* BARRETT, D. A.
KYLE, D. *see* KRISHNA, S.

L'EORME, R. M., PULLAR, T., MCKENDRICK, A. D., MCDEVITT, D. G. & MACDONALD, T. M. Switching of non-steroidal anti-inflammatory drugs in primary care: a population-based study, 493P
LACEY, L. F. *see* DIXON, J. S.
LACEY, L. F. *see* KEMPSFORD, R. D.
LACOURCIERE, Y. *see* BEAULIEU, M.
LAFONTAN, M. *see* BARBE, P.
LAMB, R. J., EVANS, H. M., MERCER, A. J., PECK, A. W., POSNER, J., BINNIE, C. D., KNOTT, S. & CHESTERMAN, L. P. The acute effects of phenytoin and lamotrigine on nerve conduction velocity and latency of the somatosensory evoked potential in healthy volunteers, 170
LANG, C. C. *see* BARR, C. S.
LANG, C. C. *see* CHOY, A. M.
LANG, C. C. *see* STURROCK, N. D. C.
LANG, C. C., CHOY, A. M. J., PRINGLE, T. H., MCNEIL, G. P., MCALPINE, H. M. & STRUTHERS, A. D. Atrial natriuretic factor improves renal function and lowers systolic blood pressure in cardiac allograft recipients, 142P
LANGGUTH, P. *see* WEBER-GRANDKE, H.
LANGLEY, S. J. *see* DIXON, J. S.
LARKIN, J. G., MCKEE, P. J. W., THOMPSON, G. G. & BRODIE, M. J. Peripheral benzodiazepine receptors in platelets of epileptic patients, 71
LAROCHE, J. *see* PUE, M. A.
LAURENT-KENESI, M.-A., FUNCK-BRENTANO, C., POIRIER, J.-M., DECOLIN, D. & JAILLON, P. Influence of CYP2D6-dependent metabolism on the steady-state pharmacokinetics and pharmacodynamics of metoprolol and nicardipine, alone and in combination, 531
LE QUAN SANG, LEVENSON, J., DEL PINO, M., SIMON, A. & DEVYNCK, M.-A. *In vivo* shear flow and erythrocyte membrane fluidity in hypertensive patients, 437
LEAKEY, T. E. B. & BERRY, D. J. The plasma caffeine:paraxanthine ratio: a true test of liver function, 156P
LEE, M. R. *see* LI KAM WA, T. C.
LEES, K. R. *see* BAINBRIDGE, A. D.
LEITCH, A. *see* THOMPSON, A.
LENNARD, L., HALE, J. P. & LILLEYMAN, J. S. Red blood cell hypoxanthine phosphoribosyltransferase activity measured using 6-mercaptopurine as a substrate: a population study in children with acute lymphoblastic leukaemia, 277
LENNARD, M. S. *see* BARHAM, H. A.
LENNARD, M. S. *see* ROWLAND, K.
LENNARD, M. S. *see* TUCKER, G. T.
LEUBE, J. *see* WEBER, C.
LEVENSON, J. *see* LE QUAN SANG
LEVINE, L. *see* BACHMANN, K. A.
LEVOL, R. *see* RANE, A.
LI KAM WA, T. C., FREESTONE, S., SAMSON, R. R., JOHNSTON, N. R. & LEE, M. R. A comparison of the effects of two putative 5-hydroxytryptamine renal prodrugs in normal man, 19
LI KAM WA, T. C., FREESTONE, S., SAMSON, R. R., JOHNSTON, N. R. & LEE, M. R. A comparison of the renal and neuroendocrine effects of two 5-hydroxytryptamine renal prodrugs in normal man, 141P
LI, S.-J. *see* GRANT, M. H.
LILLEYMAN, J. S. *see* LENNARD, L.
LIMIDO, G. *see* TARTARA, A.
LIN, C. C. *see* SCHWARTZ, J. I.
LIN, L. *see* TUCKER, G. T.
LINDUP, W. E. *see* COSTIGAN, M. G.
LINDUP, W. E. *see* ZHANG, J. G.
LINES, C. *see* TRAUB, M.
LIPWORTH, B. J. & DAGG, K. D. Enhanced sensitivity of the pulmonary vascular bed to the vasoconstrictor effects of angiotensin, 140P
LIPWORTH, B. J. *see* NEWNHAM, D. M.
LIPWORTH, B. J. *see* WHEELDON, N. M.
LIPWORTH, B. J., WHEELDON, N. M., NEWNHAM, D. M., MCFARLANE, L. C. & MCDEVITT, D. G. Regulation of $\beta_2$-adrenoceptors by sex steroid hormones during the menstrual cycle, 495P
LIU, Z. *see* RANE, A.
LO, A. C. T. *see* CHAN, K.
LOCKHART, E. A. *see* CHARMAN, W. N.
LOGAN, C. *see* COOPER, A. E.
LOI, C.-M., PARKER, B. M., CUSAK, B. J. & VESTAL, R. E. Individual and combined effects of cimetidine and ciprofloxacin on theophylline metabolism in male nonsmokers, 195
LONGSHAW, R. *see* BRIDGMAN, K.
LOPEZ-GIL, J. A. *see* CAREY, C.
LOSOWSKY, M. *see* ABOSEHMAH, A. Z. M.
LUA, S. *see* PUE, M. A.
LUBMAN, D. *see* SIMPSON, M. D. C.
LUCAS, C. *see* EKINS, S.
LUU, T. N. *see* DASHWOOD, M. R.
LYONS, D., FOWLER, G., PETRIE, J. C. & WEBSTER, J. The haemodynamic effects of GR 32191, a thromboxane $A_2$ receptor antagonist, in patients with renal artery stenosis and hypertension, 271
LYONS, D., FOWLER, G., WEBSTER, J. & PETRIE, J. C. An evaluation of colestipol at varying dosage intervals in the treatment of moderate hypercholesterolaemia, 180P

MACDONALD, N. J., ELLIOTT, H. L., HUGHES, D. M. & REID, J. L. A

comparison in young and elderly subjects of the pharmacokinetics and pharmacodynamics of single and multiple doses of benazepril, 201
MACDONALD, N. J., SIOUFI, A., HOWIE, C. A., WADE, J. R. & ELLIOTT, H. L. The effects of age on the pharmacokinetics and pharmacodynamics of single oral doses of benazepril and enalapril, 205
MACDONALD, T. M. *see* L'EORME, R. M.
MACDONALD, T. M., DUNCAN, I., MCGILCHRIST, M., BEARDON, P. H. G. & MCDEVITT, D. G. Antibiotics and symptomatic vaginal candidiasis: exploring the relationship, 492P
MACEWEN, E., RODGERS, E. H. & GRANT, M. H. Induction of drug metabolism enzymes in human breast cancer cells, 161P
MACFADYEN, R. J. *see* BAINBRIDGE, A. D.
MACKIE, A. *see* NEWNHAM, D. M.
MADDEN, S., WOOLF, T. F., POOL, W. F. & PARK, B. K. An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine: *in vitro* studies with human liver microsomes, 145P
MAGGS, J. L. *see* HARRISON, A. C.
MAKARANANDA, K. *see* PRESCOTT, L. F.
MAMZORIDI, K. & NIOPAS, I. Quantitation of indomethacin and mefenamic acid in human plasma using reversed-phase high-performance liquid chromatography, 500P
MANDEMA, J. W. *see* VAN STEVENINCK, A. L.
MANNI, R. *see* TARTARA, A.
MANT, T. *see* ROSE, J.
MARCHANT, N. C. *see* EKINS, S.
MARCHI, G. *see* PACIFICI, G. M.
MARCHISELLI, R. *see* GATTI, G.
MARGOLSKEE, D. J. *see* SCHWARTZ, J. I.
MARSHALL, R. W. *see* RICHENS, A.
MARTIN, A. J. *see* ROBERTS, G. W.
MARTIN, I. J., DUNCAN, J. N., PARTON, A. H., SPEED, W. & KING, L. J. The use of thermospray mass spectrometry (TSP/LC/MS) to identify the metabolites of (−)2-(di-*N*-propylamino)-tetralin (DPAT) in rat isolated hepatocytes, 163P
MARTIN, J. F. *see* BAUDOUIN, S. V.
MARTINELLI, V., BOCCHETTA, A., PALMAS, A. M. & DEL ZOMPO, M. An interaction between carbamazepine and fluvoxamine, 615
MASOOD, A. R. *see* THOMAS, S. H. L.
MASSART, D. L. *see* VERCRUYSSE, J.
MATTHEWS, J. *see* DE MEY, C.
MATTIE, H. *see* SCHIEVINK, H. I.
MAUREL, P. *see* CURI-PEDROSA, R.
MCALPINE, H. M. *see* LANG, C. C.
MCCLAREN, P. M. *see* BALL, C. J.
MCCLELLAND, P. *see* COSTIGAN, M. G.
MCDEVITT, D. G. *see* GERRARD, L.
MCDEVITT, D. G. *see* L'EORME, R. M.
MCDEVITT, D. G. *see* LIPWORTH, B. J.
MCDEVITT, D. G. *see* MACDONALD, T. M.
MCDEVITT, D. G. *see* NEWNHAM, D. M.
MCDEVITT, D. G. *see* WHEELDON, N. M.
MCDOWELL, I. *see* NUGENT, A.-M.
MCDOWELL, I. F. W. *see* BRENNAN, G. M.
MCENENY, J. *see* BRENNAN, G. M.
MCFARLANE, L. C. *see* LIPWORTH, B. J.
MCFARLANE, L. C. *see* WHEELDON, N. M.
MCGILCHRIST, M. *see* MACDONALD, T. M.
MCGILIVRAY, I. *see* GALLICANO, K.
MCGOLDRICK, T. A. *see* BARNARD, S.
MCINTYRE, W. *see* ISRAEL, B. C.
MCKAIGUE, J. P. *see* THAM, T. C. K.
MCKAY, J. A., MURRAY, G. I., WEAVER, R. J., EWEN, S. W. B., MELVIN, W. T. & BURKE, M. D. Drug metabolising enzymes in human colon and colonic neoplasia, 167P
MCKEE, P. J. W. *see* LARKIN, J. G.
MCKEE, P. J. W., BLACKLAW, J., CARSWELL, A., GILLHAM, R. A. & BRODIE, M. J. Double dummy comparison between once and twice daily dosing with modified-release carbamazepine in epileptic patients, 257
MCKEE, P. J. W., BLACKLAW, J., CARSWELL, A. & BRODIE, M. J. Double dummy comparison between once- and twice-daily dosing with modified-release carbamazepine in epileptic patients, 171P
MCKEE, P. J. W., PERCY-ROBB, I. & BRODIE, M. J. Therapeutic drug monitoring improves seizure control and reduces anticonvulsant side-effects in epileptic states, 181P
MCKENDRICK, A. D. *see* L'EORME, R. M.
MCKINSTRY, C. *see* RASHID, J.
MCLACHLAN, A. J., TETT, S. E., CUTLER, D. J. & DAY, R. O. Absorption and *in vitro* dissolution of hydroxychloroquine in fed subjects assessed using deconvolution techniques, 405
MCLACHLAN, A. J., TETT, S. E., CUTLER, D. J. & DAY, R. O. Disposition of the enantiomers of hydroxychloroquine in patients with rheumatoid arthritis following multiple doses of the racemate, 78
MCMILLAN, T., HAMLEY, J. & PULLAR, T. 'Compliance' with prescribed medication in hospital inpatients, 500P
MCMURDO, M. *see* CHOY, A. M.
MCNEILL, G. P. *see* LANG, C. C.
MEINEKE, I. *see* DE MEY, C.
MEINEKE, I. *see* EAGLE, S.
MELVIN, W. T. *see* MCKAY, J. A.
MELVIN, W. T. *see* WEAVER, R. J.
MERCER, A. J. *see* LAMB, R. J.
MERCER, A. J. *see* RICHENS, A.
MEREDITH, P. A. *see* AHMED, J. H.
MEREDITH, P. A. *see* BAINBRIDGE, A. D.
MEREDITH, P. A. *see* UEDA, S.
MESTRE, D. *see* BLIN, O.
MEYER, U. A. *see* ANDERSON, T.
MICHELUCCI, R. *see* GATTI, G.
MILLER, K. *see* BACHMANN, K. A.
MILNE, A. A. Y., RESTRICK, L. J., SAMPSON, A. P., COSTELLO, J. F. & PIPER, P. J. Soluble intercellular adhesion molecule-1 (ICAM-1) in broncheolar lavage fluid (BALF) and peripheral blood of asthmatic and normal subjects, 498P
MINERS, J. O. *see* ANDERSON, T.
MINTON, N. A., HUSEYIN, T. S. & HENRY, J. A. Relationships between pharmacokinetics and non-pulmonary pharmacodynamic effects of theophylline in healthy subjects, 497P
MITCHELL, R. *see* BARRY, M.
MOHRKE, W. *see* WEBER-GRANDKE, H.
MONKHOUSE, D. C. *see* CHARMAN, W. N.
MOODY, G. *see* COOPER, A. E.
MOORE, M. R. *see* ODBER, J.
MORDEN, A. E. *see* SMITH, M. R.
MORINI, R. *see* TARTARA, A.
MORRISON, P. *see* ROSE, J.
MORRISON, P. J. *see* BALL, C. J.
MUDDLE, J. R. *see* DASHWOOD, M. R.
MUKHERJEE, D. *see* HUSSEIN, Z.
MULFORD, D. J. *see* HUSSEIN, Z.
MURRAY, G. I. *see* MCKAY, J. A.
MUTSCHLER, E. *see* WEBER-GRANDKE, H.

NADEAU, A. *see* BEAULIEU, M.
NATION, R. L. *see* HAYBALL, P. J.
NATION, R. L. *see* ROBERTS, G. W.
NEELY, D. *see* NUGENT, A.-M.
NEWLANDS, A. *see* JONES, B. C.
NEWLANDS, A. J. *see* EKINS, S.
NEWNHAM, D. M. *see* LIPWORTH, B. J.
NEWNHAM, D. M., INGRAM, C. G., MACKIE, A. & LIPWORTH, B. J. Airways response to the $\beta_3$-adrenoceptor, 499P
NEWNHAM, D. M., INGRAM, C. G., MACKIE, A. & LIPWORTH, B. J. β-adrenoceptor subtypes

mediating the airways response to BRL 35135 in man, 567
NEWNHAM, D. M., MCDEVITT, D. G. & LIPWORTH, B. J. Comparison of extrapulmonary $\beta_2$-adrenoceptor responses and pharmacokinetics of salbutamol given by standard metered dose-inhaler and modified actuator device, 443P, 450
NG, H. W. K., WALLEY, T. & THOMAS, S. H. L. Impedance cardiography, 88
NGUYEN, T. *see* WALKER, J. S.
NICHOLLS, D. P. *see* BRENNAN, G. M.
NICHOLLS, D. P. *see* NUGENT, A.-M.
NIOPAS, I. *see* MAMZORIDI, K.
NORMAN, T. R. *see* BUIST, A.
NOTARIANI, L. J. *see* BENNETT, P. N.
NUGENT, A.-M., NEELY, D., YOUNG, I., MCDOWELL, I., O'KANE, M., BELL, N., STANFORD, C. F. & NICHOLLS, D. P. Stress responses after treatment of hypercholesterolaemia with simvastatin, 474
NYE, F. *see* BARRY, M.
NYE, F. *see* HOWE, J. L.
NYE, F. J. *see* BARRY, M.

O'GORMAN, D. J. *see* THOMAS, P.
O'KANE, M. *see* NUGENT, A.-M.
ODBER, J., MOORE, M. R., GOLDBERG, A. & GILLESPIE, J. S. The effects of haem synthesis blocking agents on hepatic and neural mitochondrial function, 502P
ODBER, J., MOORE, M. R., GOLDBERG, A. & GILLESPIE, J. S. The effects of haem precursors 5-aminolaevulinic acid and porphobilinogen on a range of innervated muscle preparations, 503P
ODINK, J. *see* HARTMANN, D.
OHLSSON, S. V. *see* PEDERSEN, S.
OLIVER, S. *see* BENNETT, P. N.
ORMESHER, S. *see* BARRY, M.
ORMSBY, E. *see* GALLICANO, K.
OWEN, F. *see* BALDERSON, D. J.
OWEN, F. *see* ROBERTS, D. A.

PACIFICI, G. M. & MARCHI, G. Interindividual variability of phenol- and catechol-sulphotransferases in platelets from adults and newborns, 593
PAKUTS, A. *see* GALLICANO, K.
PALMAS, A. M. *see* MARTINELLI, V.
PAN, H. Y. *see* TRISCARI, J.
PARK, B. K. *see* BARNARD, S.
PARK, B. K. *see* HARRISON, A. C.
PARK, B. K. *see* MADDEN, S.
PARK, B. K. *see* PIRMOHAMED, M.
PARK, B. K. *see* TINGLE, M. D.
PARKER, B. M. *see* LOI, C.-M.
PARTON, A. H. *see* MARTIN, I. J.
PAUT, O. *see* BLIN, O.
PAXTON, J., ROBERTS, P. & SKEET, P. Measurement of the toxic effects of three acridine antitumour agents towards rat hepatocytes, 149P
PECK, A. W. *see* LAMB, R. J.
PEDERSEN, S., STEFFENSEN, G. & OHLSSON, S. V. The influence of orally deposited budesonide on the systemic availability of budesonide after inhalation from a Turbuhaler, 211
PERCY-ROBB, I. *see* MCKEE, P. W. J.
PERUCCA, E. *see* GATTI, G.
PERUCCA, E. *see* TARTARA, A.
PESTANA, M. *see* VIEIRA-COELHO, M. A.
PETRIE, J. C. *see* BROWN, F. T.
PETRIE, J. C. *see* LYONS, D.
PHILIPPON, F. *see* FISET, C.
PICHARD, L. *see* CURI-PEDROSA, R.
PIPER, P. J. *see* COOK, A. J.
PIPER, P. J. *see* MILNE, A. A. Y.
PIRMOHAMED, M., ALLOTT, R., KITTERINGHAM, N. R., CHOONARA, I. A., BRECKENIDGE, A. M. & PARK, B. K. Lymphocyte microsomal epoxide hydrolase activity in patients on chronic anticonvulsant therapy, 159P
PISANI, F. *see* GATTI, G.
POIRIER, J.-M. *see* LAURENT-KENESI, M. A.
POLLAK, P. T., SHARMA, A. D. & CARRUTHERS, S. G. Creatinine elevation in patients receiving amiodarone correlates with serum amiodarone concentration, 125
POOL, W. F. *see* MADDEN, S.
POSNER, J. *see* HOLBROOK, J.
POSNER, J. *see* LAMB, R. J.
PRESCOTT, L. F., YOOVATHAWORN, K., MAKARANANDA, K., SAIVISES, R. & SRIWATANAKUL, K. Impaired absorption of paracetamol in vegetarians, 237
PRICE, J. F. *see* COOK, A. J.
PRINGLE, T. H. *see* CHOY, A. M.
PRINGLE, T. H. *see* LANG, C. C.
PROVENZANO, R. *see* DUCHARME, M. P.
PUE, M. *see* EAGLE, S.
PUE, M. A., SAPORITO, M., LAROCHE, J., LUA, S., BYGATE, E., DANIELS, S. & BROOM, C. An investigation of the potential interaction between digoxin and oral famciclovir in healthy volunteers, 177P
PUKRITTAYAKAMEE, S. *see* KRISHNA, S.
PULLAR, T. *see* L'EORME, R. M.
PULLAR, T. *see* MCMILLAN, T.

QUINE, M. A. *see* SMITH, M. R.

RANE, A., LEVOL, R., LIU, Z., ERICSSON, H., HANSSON, T., HENDERSON, C. & WOLF, C. R. Dopamine interactive drugs: effects on hepatic cytochrome P450 activities and expression, 149P
RASHID, J., MCKINSTRY, C., RENWICK, A. G., DIRNHUBER, M., WALLER, D. G. & GEORGE, C. F. Quercetin, an *in vitro* inhibitor of CYP3A, does not contribute to the interaction between nifedipine and grapefruit juice, 460
RAWLINS, M. D. *see* KAMALI, F.
RAWLINS, M. D. *see* THOMAS, S. H. L.
RECHERCHE, T. *see* FLOUVAT, B.
REED, J. W. *see* THOMAS, S. H. L.
REESE, J. H. *see* BACHMANN, K. A.
REEVES, D. *see* DAVEY, P.
REID, J. L. *see* BAINBRIDGE, A. D.
REID, J. L. *see* MACDONALD, N. J.
RENWICK, A. G. *see* RASHID, J.
RESTORICK, J. *see* ROSE, J.
RESTRICK, L. J. *see* MILNE, A. A. Y.
RICHENS, A. *see* GATTI, G.
RICHENS, A., MERCER, A. J., JONES, D. M., GRIFFITHS, A. & MARSHALL, R. W. Effects of zolpidem on saccadic eye movements and psychomotor performance: a double-blind, placebo controlled study in healthy volunteers, 61
RICHMOND, H. *see* COOPER, A. E.
RIDDELL, J. G. *see* THAM, T. C. K.
RIDDELL, H. G. *see* THOMPSON, A.
RIDGWAY, G. *see* DAVEY, P.
RIVIERE, D. *see* BARBE, P.
ROBERTS, B. *see* ALLARD, S.
ROBERTS, D. A. *see* BALDERSON, D. J.
ROBERTS, D. A., BALDERSON, D. J., DEAKIN, J. W. F. & OWEN, F. The abundance of $D_2$ receptor mRNA isoforms in brain samples from controls and schizophrenics, 491P
ROBERTS, G. W., NATION, R. L., JARVINEN, A. O. & MARTIN, A. J. An *in vivo* assessment of the tobramycin/ticarcillin interaction in cystic fibrosis patients, 372
ROBERTS, P. & SKEET, P. The effect of different culture media on the maintenance of liver-specific function in primary rat hepatocyte cultures, 154P
ROBERTS, P. *see* KHAN, S.
ROBERTS, P. *see* PAXTON, J.
ROBSON, R. H. Gastric lavage and induced emesis: time for a change, 496P
RODGERS, E. H. *see* GRANT, M. H.
RODGERS, E. H. *see* MACEWEN, E.
RODRIGUES, J. *see* CHOY, A. M.
ROGERS, J. D. *see* SCHWARTZ, J. I.
ROLF, C. N. *see* GUPTA, S. K.
ROOS, B. *see* WEBER, C.
ROSE, J., MANT, T., MORRISON, P., RESTORICK, J. & ACTON, G. Multiple dose safety, tolerability, renal effects and pharmacokinetics in man of FK453, a novel adenosine $A_1$ receptor antagonist, 501P
ROSHOLM, J.-U., HANSEN, L. J., HALLAS, J. & GRAM, L. F. Neuroleptic drug utilization in outpatients—a prescription database study, 579
ROSTAMI HODJEGAN, A., JACKSON,

P. R. & TUCKER, G. T. Drug *vs* metabolite measurement in bioequivalance studies: theoretical considerations, 158P
ROWLAND, K., ELLIS, S. W., LENNARD, M. S. & TUCKER, G. T. Validation of human CYP2D6 (debrosoquine 4-hydroxylase) expressed in yeast: enzyme kinetics and inhibition by antidepressant drugs, 157
RUTTER, N. *see* BARRETT, D. A.

SAEED, S. A. & SHAFIQ, M. Decreased ability of human plasma to inhibit platelet arachidonic acid metabolism in asthmatic patients, 498P
SAHAI, J. *see* GALLICANO, K.
SAIVISES, R. *see* PRESCOTT, L. F.
SALLOWSKY, E. *see* DAMMANN, H. G.
SAMARA, E. *see* HUSSEIN, Z.
SAMPSON, A. P. *see* COOK, A. J.
SAMPSON, A. P. *see* MILNE, A. A. Y.
SAMSON, R. R. *see* LI KAM WA, T. C.
SANDMANN, W. *see* KOLVENBACH, R.
SANSOM, L. N. *see* HAYBALL, P. J.
SAPORITO, M. *see* PUE, M. A.
SCHEININ, M. *see* SUNDBERG, S.
SCHIEVINK, H. I., MATTIE, H., THOMEER, R. T. W. M. & VAN STRIJEN, E. The passage of cloxacillin into cerebrospinal fluid in the absence of meningitis, 57
SCHINDLER, E. *see* BOLDT, J.
SCHMOLDT, A. *see* DAMMANN, H. G.
SCHOEMAKER, H. C. *see* DE BOER, A.
SCHOEMAKER, H. C. *see* VAN STEVENINCK, A. L.
SCHROETER, V. *see* DE MEY, C.
SCHULTZ, M. *see* DAMMANN, H. G.
SCHWARTZ, J. I., MARGOLSKEE, D. J., BJORNSSON, T. D., WILLIAMS, V. C., HSIEH, J. Y., LIN, C. C. & ROGERS, J. D. Oral pharmacokinetics and food interaction of the leukotriene $D_4$ receptor antagonist verlukast, 464
SELBY, P. *see* CORLETT, S. A.
SENARD, J. M. *see* BARBE, P.
SERTL, K. *see* BAUER, K. G.
SHAFIQ, M. *see* SAEED, S. A.
SHANKS, R. G. *see* THAM, T. C. K.
SHARMA, A. D. *see* POLLAK, P. T.
SHAW, P. N. *see* BARRETT, D. A.
SHEDLOFSKY, S. I. *see* ISRAEL, B. C.
SHENOY, E. V. B., AYRTON, J., BOWERS, G. D., DANIEL, M. J. & SURRY, D. D. The use of Hep G2 cells in predicting the routes of metabolism of fluticasone in man, 166P
SHEPHARD, A. *see* BRIDGMAN, K.
SHERIDAN, D. J. *see* THOMAS, P.
SHUMAK, S. L. *see* CAMPBELL, N. R. C.
SILKE, B. Experience with a segmental thermal clearance probe in the measurement of skin blood flow during drug intervention, 172P
SILKE, B. *see* HERITY, N. A.
SILKE, B. *see* THAM, T. C. K.
SILKE, B. *see* THOMPSON, A.
SIMON, A. *see* LE QUAN SANG
SIMON-SCHULTZ, J. *see* DAMMANN, H. G.
SIMPSON, J. *see* BARRETT, D. A.
SIMPSON, M. D. C., LUBMAN, D., SLATER, P. & DEAKIN, J. F. W. The autoradiographic distribution of abnormalities in $5HT_{1A}$ receptors in ventromedial prefrontal cortex in schizophrenia, 505P
SIOUFI, A. *see* MACDONALD, N. J.
SKETT, P. *see* KHAN, S.
SKETT, P. *see* PAXTON, J.
SKETT, P. *see* ROBERTS, P.
SKJELBO, E. *see* BRØSEN, K.
SLATER, P. *see* SIMPSON, M. D. C.
SMITH, C. *see* BRIDGMAN, K.
SMITH, D. A. *see* JONES, B. C.
SMITH, M. D. *see* HAYBALL, P. J.
SMITH, M. R., BELL, G. D., QUINE, M. A., SPENCER, G. M., MORDEN, A. E. & JONES, J. G. Small bolus injections of intravenous midazolam for upper gastrointestinal endoscopy: a study of 788 consecutive cases, 573
SOARES-DA-SILVA, P. *see* FERNANDES, M. H.
SOARES-DA-SILVA, P. *see* GUIMARAES, J. T.
SOARES-DA-SILVA, P. *see* VIEIRA-COELHO, M. A.
SOONS, P. A. *see* DE BOER, A.
SOTANIEMI, E. A. *see* COCKSHOTT, I. D.
SPAHN-LANGGUTH, H. *see* WEBER-GRANDKE, H.
SPEED, W. *see* MARTIN, I. J.
SPENCER, G. M. *see* SMITH, M. R.
SRIWATANAKUL, K. *see* PRESCOTT, L. F.
STANFORD, C. F. *see* NUGENT, A.-M.
STARK, S. *see* BAINBRIDGE, A. D.
STEFFENSEN, G. *see* PEDERSEN, S.
STEINHOFF, I. *see* DAMMANN, H. G.
STERTMANN, W. A. *see* BOLDT, J.
STEWART, F. *see* COOPER, A. E.
STEWART, V. C., TISOCKI, K., BELL, J. A., WHITING, P. H. & HAWKSWORTH, G. M. Species differences in prostaglandins synthetase/lipoxygenase-mediated cooxidation in the kidney, 164P
STIEKMA, J. C. J., VAN GRIENSVEN, J. M. T., VAN DINTHER, T. G. & COHEN, A. F. A cross-over comparison of the anti-clotting effects of three low molecular weight heparins and glycosaminoglycuronan, 51
STRADA, G. *see* TARTARA, A.
STRUTHERS, A. D. *see* BARR, C. S.
STRUTHERS, A. D. *see* CHOY, A. M .
STRUTHERS, A. D. *see* LANG, C. C.
STRUTHERS, A. D. *see* STURROCK, N. D. C.
STURROCK, N. D. C., LANG, C. C. & STRUTHERS, A. D. Indomethacin does not augment cyclosporin-induced hypertension acutely in spite of inducing renal sodium retention, 140P
SUBHAN, F. *see* THOMAS, S. H. L.
SULLIVAN, T. J. *see* BACHMANN, K. A.
SUMMERBELL, J., WYNNE, H., HANKEY, C. R. & WILLIAMS, F. M. The effect of age and frailty upon blood esterase activities and their response to dietary supplementation, 399
SUNDBERG, S., SCHEININ, M., ILLI, A., AKKILA, J., GORDIN, A. & KERANEN, T. The effects of the COMT inhibitor entacapone on haemodynamics and peripheral catecholamine metabolism during exercise, 451
SUPANARANOND, W. *see* KRISHNA, S.
SURRY, D. D. *see* SHENOY, E. V. B.
SWAGZDIS, J. *see* EAGLE, S.
SWANSON, B. M. *see* TRISCARI, J.
SWART, A. M. *see* HOWE, J. L.
SWIFT, C. G. *see* KALRA, L.
SWIFT, C. G. *see* KINIRONS, M. T.
SZWANDT, I. S. F., EDWARDS, G. & WARDS, S. A. Factors affecting the bioavailability of halofantrine in the rat, 159P

TABER, H. *see* CHOLERTON, S.
TANG, Y. S., BENJAMIN, N. & HAWKSWORTH, G. M. Nitric acid synthesis in cultured rat hepatocytes and liver slices: effect on menadione toxicity, 166P
TARTARA, A., GALIMBERTI, C. A., MANNI, R., MORINI, R., LIMIDO, G., GATTI, G., BARTOLI, A., STRADA, G. & PERUCCA, E. The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treatment, 366
TASSANEEYAKUL, W. *see* ANDERSON, T.
TASSINARI, C. A. *see* GATTI, G.
TEJA-ISAVADHARM, P. *see* KRISHNA, S.
TER KUILE, F. *see* KRISHNA, S.
TETT, S. E. *see* MCLACHLAN, A. J.
THAM, T. C. K., HERITY, N., GUY, S. & SILKE, B. Haemodynamic comparison of amlodipine and atenolol in essential hypertension using the quantascope, 555
THAM, T. C. K., MCKAIGUE, J. P., GUY, S., SHANKS, R. G. & RIDDELL, J. G. The dose dependency of the α-adrenoceptor antagonist and β-adrenoceptor partial agonist activity of dilevalol and labetalol in man, 251
THITIARCHAKUL, S. *see* WANWIMOLRUK, S.
THOMAS, M. *see* KEMPSFORD, R. D.

THOMAS, P., O'GORMAN, D. J. & SHERIDAN, D. J. Acute and chronic effects of flosequinan on resting and exercise haemodynamics in congestive heart failure, 539
THOMAS, S. H. L. *see* KAMALI, F.
THOMAS, S. H. L. *see* NG, H. W. K.
THOMAS, S. H. L., MASOOD, A. R., SUBHAN, F., REED, J. W. & RAWLINS, M. D. Effects of nebulised morphine on ventilation and breathlessness during exercise in healthy volunteers, 506P
THOMEER, R. T. W. M. *see* SCHIEVINK, H. I.
THOMPSON, A., LEITCH, A., SILKE, B. & RIDDELL, J. G. The effects of celiprolol and metoprolol on echo-Doppler cardiac performance indices in healthy volunteers, 172P
THOMPSON, G. G. *see* LARKIN, J. G.
THOMSON, M., HAYNES, W. G. & WEBB, D. J. Screening for human immunodeficiency virus: a survey of British clinical pharmacology units, 293
TILLEMENT, J.-P. *see* HERVE, F.
TIMMINGS, P. *see* GATTI, G.
TINGLE, M. D. & PARK, B. K. The use of a three compartment *in vitro* model to investigate the role of hepatic drug metabolism in drug-induced blood dyscrasias, 31
TISOCKI, K. *see* STEWART, V. C.
TOON, S. *see* DIXON, J. S.
TRAUB, M., LINES, C. & AMBROSE, J. CCK and anxiety in normal volunteers, 504P
TREVIT, R. T. *see* KINIRONS, M. T.
TRISCARI J., SWANSON, B. M., WILLARD, D. A., COHEN, A. F., DEVAULT, A. & PAN, H. Y. Steady state serum concentrations of pravastatin and digoxin when given in combination, 263
TUCKER, G. T. *see* BARHAM, H. A.
TUCKER, G. T. *see* ROSTAMI HODJEGAN, A.
TUCKER, G. T. *see* ROWLAND, K.
TUCKER, G. T., LENNARD, M. S., ELLIS, S. W., WOODS, H. F., LIN, L., HIRATSUKA, A., CHU, T. & CHO, A. K. 'Ecstasy' is demethylated by human cytochrome P4502D6 (CYP2D6), 144P
TUK, B. *see* VAN STEVENINCK, A. L.
TURGEON, J. *see* FISET, C.
TURNER, P. Clinical pharmacology: its efficacy and prospects, 13
TUTE, M. *see* JONES, B. C.

UEDA, S., MEREDITH, P. A., HOWIE, C. A. & ELLIOTT, H. L. A comparative assessment of the duration of action of amlodipine and nifedipine GITS in normotensive subjects, 561
UR, E. *see* WRIGHT, D. M.

VAN BRUMMELEN, P. *see* WEBER, C.
VAN DIJK, J. G. *see* VAN STEVENINCK, A. L.
VAN DINTHER, T. G. *see* STIEKMA, J. C. J.
VAN GRIENSVEN, J. M. T. *see* STIEKMA, J. C. J.
VAN STEVENINCK, A. L., MANDEMA, J. W., TUK, B., VAN DIJK, J. G., SCHOEMAKER, H. C., DANHOF, M. & COHEN, A. F. A comparison of the concentration-effect and relationships of midazolam for EEG-derived parameters and saccadic peak velocity 109
VAN STRIJEN, E. *see* SCHIEVINK, H. I.
VANCHEESWARAN, R., DASHWOOD, M. R., AZAM, A. & BLACK, C. M. A combined immunocytochemical and autoradiographic study of endothelin-1 and its binding sites in systemic sclerosis, 489P
VEAL, G. J., WILD, M. J. & BLACK, D. J. Intracellular metabolism of zidovudine by human isolated peripheral blood mononuclear cells, 160P
VERCHER, J. L. *see* BLIN, O.
VERCRUYSSE, J., MASSART, D. L. & DUPONT, A. G. Effect of nicardipine on the disposition of the enantiomers of propranolol in rats, 151P
VERE, D. W. *see* CAREY, C.
VERONESE, M. E. *see* ANDERSON, T.
VESTAL, R. E. *see* LOI, C.-M.
VIEIRA-COELHO, M. A., FERNANDES, M. H., PESTANA, M. & SOARES-DA-SILVA, P. Effect of type A and B monoamine oxidase inhibitors on the urinary excretion of dopamine, 5-hydroxytryptamine and amine metabolites, 153P
VIRIYAYUDHAKORN, S. *see* WANWIMOLRUK, S.

WADE, J. R. *see* MACDONALD, N. J.
WALKER, J. S., ARROYO, J. F., NGUYEN, T. & DAY, R. O. Analgesic efficacy of non-steroidal anti-inflammatory drugs in experimental pain in humans, 417
WALLACE, H. M. *see* ANDERSON, R. M.
WALLER, D. G. *see* DONALDSON, K. M.
WALLER, D. G. *see* RASHID, J.
WALLER, P. C. *see* DE BOER, A.
WALLEY, T. PACTLINE: a program to allow practical utilisation of PACT data, 506P
WALLEY, T. Rational prescribing in primary care—a new role for clinical pharmacology, 11
WALLEY, T. *see* NG, H. W. K.
WANOGHO, E. & BURKE, M. D. Fluoroquinolone inhibition of cytochrome P450, 168P
WANWIMOLRUK, S., WONG, S. M., COVILLE, P. F., VIRIYAYUDHAKORN, S. & THITIARCHAKUL, S. Cigarette smoking enhances the elimination of quinine, 610
WADBURTON, D. M. *Ginkgo biloba* extract and cognitive decline, 137
WARDS, S. A. *see* SZWANDT, I. S. F.
WATT, A. H. *see* KILGOUR-CHRISTIE, J.
WEAVER, R. J. *see* MCKAY, J. A.
WEAVER, R. J., WEBSTER, D., MELVIN, W. T., DICKINS, M. & BURKE, M. D. Human cytochrome P4502C metabolism, 167P
WEBB, D. J. *see* THOMSON, M.
WEBER, C., BIRNBOCK, H., LEUBE, J., KOBRIN, I., KLEINBLOESEM, C. H. & VAN BRUMMELEN, P. V. Multiple dose pharmacokinetics and concentration effect relationship of the orally active renin inhibitor remikiren (Ro 42-5892) in hypertensive patients, 547
WEBER, C., ROOS, B., BIRNBOECK, H. & VAN BRUMMELEN, P. Effect of food on the oral bioavailability of the renin inhibitor remikiren (Ro 42-5892), 177P
WEBER-GRANDKE, H., HAHN, G., MUTSCHLER, E., MOHRKE, W., LANGGUTH, P. & SPAHN-LANGGUTH, H. The pharmacokinetics of tranylcypromine enantiomers in healthy subjects after oral administration of racemic drug and the single enantiomers, 363
WEBSTER, D. *see* WEAVER, R. J.
WEBSTER, J. *see* LYONS, D.
WEISMAN, S. *see* CHARMAN, W. N.
WELLER, I. V. D. *see* HOWE, J. L.
WHEELDON, N. M. *see* GERRARD, L.
WHEELDON, N. M. *see* LIPWORTH, B. J.
WHEELDON, N. M., MCDEVITT, D. G. & LIPWORTH, B. J. Cardiac effects of the $\beta_3$-adrenoceptor agonist BRL 35135 in man, 494P
WHEELDON, N. M., MCDEVITT, D. G., MCFARLANE, L. C. & LIPWORTH, B. J. β-adrenoceptor subtypes mediating the metabolic responses to BRL 35135 in man, 493P
WHITE, N. J. *see* KRISHNA, S.
WHITING, P. H. *see* STEWART, V. C.
WICKERT, W. A. *see* CAMPBELL, N. R. C.
WILD, M. J. *see* VEAL, G. J.
WILKES, M. P. *see* KEY, B. J.
WILLARD, D. A. *see* TRISCARI, J.
WILLIAMS, F. M. *see* SUMMERBELL, J.
WILLIAMS, J. A. *see* EKINS, S.
WILLIAMS, V. C. *see* SCHWARTZ, J. I.
WOLF, C. R. *see* RANE, A.
WONG, S. M. *see* WANWIMOLRUK, S.
WONG, V. *see* ABOSEHMAH, A. Z. M.
WOODS, H. F. *see* BARHAM, H. A.
WOODS, H. F. *see* TUCKER, G. T.
WOOLF, T. F. *see* MADDEN, S.

WRIGHT, D. M., UR, E., BOULOUX, P. M. G. & GROSSMAN, A. Neuroendocrine effects of the kappa-selective agonist spiradoline (U-62, 066E) in man, 143P
WRITER, D. *see* EAGLE, S.
WYNNE, H. *see* SUMMERBELL, J.
YAQOOB, M. *see* COSTIGAN, M. G.
YEUNG, J. H. K. *see* CHAN, K.
YOOVATHAWORN, K. *see* PRESCOTT, L. F.
YORK, P. *see* ABOSEHMAH, A. Z. M.
YOUNG, I. *see* NUGENT, A.-M.
ZACCARA, G. *see* GATTI, G.
ZHANG, J. G. & LINDUP, W. E. Cisplatin-induced damage to renal mitochondria, 179P
ZICKMANN, B. *see* BOLDT, J.
ZIMMERMAN, D. M. *see* BRUNELLE, R. L.

# SUBJECT INDEX

This index was compiled from the keywords

(P = proceedings)


ACE inhibitors, 376
Absorption, 221
Acetylator status, 148P
Acridine antitumour agents, 149P
Acute lymphoblastic leukaemia, 277
Acyl-glucuronides, 186
Adenosine, 134
Adenosine $A_1$ receptor antagonist, 501P
Adults, 593
Adverse drug reactions, 89
Adverse drug reactions—a reply, 90
Age, 148P, 201, 205, 391, 399, 573
Agonist-antagonist, 351
Airways response, 567
Aldosterone, 19
α-adrenoceptor, 251
$\alpha_1$-acid glycoprotein, 241
Ambulatory blood pressure, 323
L-amino acid decarboxylase, 152P
3′-amino-3′deoxythymidine, 161P
5-amino laevulinic acid, 503P
Amiodarone, 125
Amitriptyline, 376
Amlodipine, 555, 561
Analgesic, 351
Analgesic models, 417
Angiotensin II, 140P
Antibiotics, 492P, 511
Anticholinesterase, 145
Anticonvulsant therapy, 159P
Antidepressant drugs, 157P
Antidepressants, 376
Antiepileptic drugs, 71
Antimalarials, 585
Antimicrobial chemotherapy, 511
Antimicrobial therapy, 511
Antioxidant treatment, 175P
Anxiety, 504P
Anxiolytic, 357
Arachidonic acid, 498P
L-arginine, 45
Asthma, 285, 498P
Atenolol, 315, 427, 502P, 555
Atherosclerosis, 490P
Atrial natriuretic factor, 142P
Atropine, 480

β-adrenoceptor, 251
β-adrenoceptor subtypes, 493P
$\beta_2$-adrenoceptors, 495P
$\beta_3$-adrenoceptor, 499P
$\beta_3$-adrenoceptor antagonist, 494P, 567
BRL 35135, 493P, 494P, 499P, 567
Benazepril, 201, 205
1, 2-benzanthracene, 162P
Benzodiazepine, 117
Benzodiazepines, 71
Bioavailability, 135, 159P, 176P, 177P, 405, 488P
Bioequivalence studies, 158P
Blood pressure, 331
Bolus *vs* titration dose, 573
Breast cancer, 161P
Breast feeding, 413
Breast milk, 133
Broncheolar lavage fluid, 498P
Budesonide, 211
Buprenorphine, 215

CCK, 504P
COMT inhibition, 451
CYP isoforms, 521
CYP2C, 380
CYP2C9, 143P
CYP2D6, 144P, 531
CYP3A, 460
CYP3A4, 457
Caffeine:paraxanthine ratio, 156P
Calcitonin, 11
Cancer, 229
Candidiasis, 492P
Captopril, 142P
Carbamazepine, 171P, 257, 615
Cardiac allograft, 142P
Cardiac effects, 93
Cardiac output, 181P
Cardiac surgery, 309
Cardiovascular, 470
Casodex, 339
Catecholamines, 25, 427, 451
Celiprolol, 172P
Cerebral ischaemia, 134
Cerebrospinal fluid, 57
Cholesterol, 607
Cholesterol measurement, 607
Cimetidine, 195
Ciprofloxacin, 195
Cisplatin, 179P
Clinical data storage, 173P
Clinical pharmacologists, 507
Clinical pharmacology, 11, 13, 483P
Clinical trial, 257
Clinical trials, 293
Clonidine, 25
Cloxacillin, 57
Clozapine, 149P
Cochrane collaboration, 507
Cognitive decline, 137
Colestipol, 180P
Colon, human, 167P
Colonic neoplasia, 167P
Compliance, 500P, 503P
Computerised psychomotor performance, 376
Concentration-effect relationship, 109
Congestive heart failure, 174P, 539
Continuing medical education, 511
Controlled-release, 470
Corticosteroids, 11
Cortisol, 474
Cortisol D4 reductase, 160P
Cortisol 6β-hydroxylase, 160P
Creatinine, 125
Creatinine clearance, 186
Cyclo-oxygenase, 186
Cyclo-oxygenase products, 303
Cyclosporin, 140, 457
Cystic fibrosis, 372, 494P
Cytochrome P450, 143P, 149P, 154P, 168P, 457
Cytochrome P450 CYP2D6, 157P
Cytochrome P4502C, 167P
Cytochrome P4503A, 165P
Cytochrome P4503A4, 156P
Cytokines, 229

Danshen, 147P
Dapsone, 31
Database, 579
Debrisoquine 4-hydroxylase, 157P
Deconvolution, 405
Defaecation, 481
Detrusor muscle, 479, 480
Diclofenac, 345
Didanosine, 87
Diflunisal, 417
Digoxin, 177P, 263
Dilevalol, 251
(−) 2-(di-*N*-propylamino)-tetralin, 163P
Diuretic, 607
Diuretics, 1
Dopamine, 149, 151P, 153P
Dopamine $D_2$ receptor mRNA, 491P
Dose, 579
Dose proportionality, 464
Dose regimen, 215
Doxazosin, 599
Driving performance, 67
Drug interaction, 345, 366, 531, 603
Drug interactions, 195, 263
Drug metabolising enzymes, 161P
Drug metabolism, 195, 610
Drug trial, 369
Drug utilization, 483P
Drug-binding, 241

EEG, 109
Eating, 427
Ebastine, 67
Echo-Doppler, 172P
Ecstasy, 144P
Education, 511
Efficacy, 13
Elderly, 174P, 383, 579
Elderly subjects, 467
Electrical stimulation, 417
Enalapril, 205, 599
Enantiomers, 78, 151P, 339, 363, 488, 531
Endogenous tissue-type plasminogen activator, 99
Endoscopy, 573
Endothelin 1, 489P, 490P
Endothelin A antagonist, 490P
Endothelium-derived relaxing factor, 45

Enoximone, 309
Entacapone, 451
Enzyme induction, 155P, 610
Epilepsy, 71, 171P, 181P, 257, 603
Epoxide hydrolase, 159P
Erythrocytes, 87, 437
Esterases, 399
Ethics, 293
European Association of Clinical Pharmacology, 183P
European network of therapeutics teachers, 275P
Exercise, 506P
Exercise testing, 474
Experimental pain, 417
Extrapulmonary responses, 443
Extroversion, 369

FK453, 501P
FR 139317, 490P
Famciclovir, 177P
Fat absorption, 266
Felodipine ER, 323
Fenoterol dry powder, 285
Finger tremor, 285
First and second pain, 417
Flatus, 481
Flosequinan, 539
Flumezanil, 168P
Fluorine substitution, 147P
Fluoroquinolone, 168P
Fluticasone, 135, 136, 166P
Fluvoxamine, 615
Food, 177P, 405, 427
Food effect, 470
Food interaction, 464
Forearm vascular resistance, 331
Forearm vein, 303
Formulary, 179P
Fosinopril, 331
Frailty, 399
Frusemide, 607
Furan dicarboxylic acid, 164P

γ-L-glutamyl-5-hydroxy-L-tryptophan, 19, 141P
GABA, 117
GR32191, 271
GR85548, 170P
Gastric lavage, 496P
Genetic, 241
*Ginkgo biloba*, 137
Glucocorticoids, 153P
Glucuronidation, 357
Glyceryl trinitrate, 481, 499P
Grapefruit juice, 457, 460

HEP G2 cells, 166P
HIV, 82, 146P, 293
HT115 cells, 150P
5-$HT_{1A}$ receptor mRNA, 490P
Haem precursors, 503P
Haem synthesis, 502P
Haemodynamic effects, 315
Haemodynamics, 45, 309, 451
Halofantrine, 159P, 176P
Halofantrine, parenteral, 585
Haloperidol, 149P
Hepatic impairment, 339
Hepatic metabolism, 229
Hepatocyte cultures, 154P
Hepatocytes, 149P
Hepatotoxicity, 147P
Histamine, 39
Human, 303
Human immunodeficiency virus, 146P, 160P
Human microsomal metabolism, 521
Humans, 195
Hydroxychloroquine, 78, 145P, 405
7-hydroxycoumarin, 180P
5-hydroxy-L-tryptophan, 19, 141P
5-hydroxytryptamine, 19, 141P, 153P
5-hydroxytryptamine$_{1A}$ receptors, 505P
5-hydroxytrytamine receptor agonist, 170P
Hypercholesterolaemia, 180P
Hypercholesterolaemia, type II, 175P
Hypertension, 140, 173P, 271, 323, 437, 555
Hypnotic, 61
Hypoxanthine phosphoribosyltransferase, 277

Ibuprofen, 417
Ifosfamide, 488P
Imipramine, 241
Impaired absorption, 237
Impedance cardiography, 88, 427
Impedance cardiography—a reply, 89
Indomethacin, 82, 140, 413, 500P
Induced emesis, 497P
Induction, 161P
Inhalation, 211
Insulin, 153P
Interaction, 177P, 372, 460, 599, 615
Interaction study, 323
Interactions, 99
Intercellular adhesion molecule-1, 498P
Interferon-alpha, 229
Intra-subject variability, 128
Intravenous infusion, 215
Isoenzymes, 154P

κ-selective agonist, 143P
Ketoprofen enantiomers, 186
Kidney, 19, 151P
Kidney transplant, 164P
Kinetics, 521

LDL oxidation, 175P
Labetalol, 251
Lactation, 413
Lamotrigine, 170P
Lansoprazole, 156P, 391, 467
Leukotriene $E_4$, 494P
Lipase inhibitor, 266
Lipids, 607
Lipoprotein, 607
Lipoxygenase, 164
Liver function, 156P
Low molecular weight heparins, 51
Low urinary recovery, 237
Low-dose aspirin, 470
Lung function, 285, 494P

MCF7 cells, 162P
Magnesium, 1
Malaria, 105, 157P, 585
Malaria treatment, 585
Mefanamic acid, 500P
Membrane fluidity, 437
Menadione, 156P
Meningitis, 57
Menstrual cycle, 495P
Meperidine, 351
Mephenytoin, 105
6-mercaptopurine, 277
Metabolic response, 493P
Metabolism, 31, 87, 166P, 167P, 237
Methylenedioxymethamphetamine, 144P
*N*-methyl nalorphine, 169P
Metoclopramide, 149P
Metoprolol, 172P, 531
Mianserin, 133
Microcirculation, 309
Midazolam, 109, 117, 168P, 573
Mifepristone, 241
Migraine, 170P
Minaprine, 376
Misoprostol, 345
Mitochondrial function, hepatic, 502P
Mitochondrial function, neural, 502P
Mitoxantrone, 162P
Modified actuator device, 445, 496P
Modified-release formulation, 257
Monoamine oxidase, 152P
Monoamine oxidase activity type A, 152P
Monoamine oxidase activity type B, 152P
Monoamine oxidase inhibition, 151P
Monoamine oxidase inhibitors type A, 153P
Monoamine oxidase inhibitors type B, 153P
Morphine, 506P
Motion perception, 117
Multiple dose, 467

NSAIDs, 413
Naproxen, 82
Nephrotoxicity, 179P
Nerve-mediated relaxation, 479
Neuroleptic drugs, 579
Newborns, 593
Nicardipine, 151P, 531
Nicotine, 173P, 221
Nifedipine, 315, 460, 499P, 502P
Nifedipine GITS, 561
Nifedipine interactions, 99
Nisoldipine, 315
Nitrendipine, 437
Nitric oxide, 166P, 181P
Nizatidine, 380
Non-esterified fatty acids, 25
Non-steroidal anti-inflammatory drugs, 493P
Nutrition, 399

Omeprazole, 156P, 380, 521
Opioid, 351
Oral application, 547
Orgaran, 51
Orlistat, 266
Oxcarbazepine, 366

P450 metabolism, 229
PACTLINE, 506P
Paracetamol, 147P, 157P, 237
Pazinaclone, 357
Personality, 369
Pethidine, 351
Pharmacodynamics, 201, 205, 391, 497P, 547
Pharmacoepidemiology, 579
Pharmacogenetics, 105, 531
Pharmacokinetics, 1, 78, 87, 93, 99, 128, 170P, 175P, 178P, 186, 201, 205, 215, 221, 339, 345, 357, 363, 366, 391, 467, 488P, 496P, 497P, 501P, 505P, 547, 585, 610
Phenobarbitone, 366, 503P
Phenytoin, 170P, 380, 505P, 603
Phosphodiesterase inhibitor, 309
Piroximone, 309
Placebo, 351
Plasma noradrenaline concentrations, 331
Plasma potassium, 285
Plasma renin activity, 427
Platelets, 593
Population pharmacometrics, 547
Population study, 173P
Porphobilinogen, 503P
Postgraduate, 511
Postmarketing surveillance, 492P
Postoperative pain, 351
Pravastatin, 263
Premature newborn, 215
Prescription analysis and cost, 506P
Pressor responses, 561
Primary care, 11
Proguanil, 105
Propranolol, 151P
Prostacyclin, 303
Prostaglandin synthetase, 164P
Protein binding, 186
Proton pump inhibitor, 175P
Psychomotor performance, 61, 383, 502P
Pulmonary hypertension, 45
Pulmonary vascular bed, 140P

Quantascope, 555
Quercetin, 460
Quinine, 610

Raclopride, 149P
Ramipril, 323
Randomised controlled trials, 507
Ranitidine, 178P, 345
Rational prescribing, 11
Reactive oxygen species, 150P
Receptor antagonist, 271
Receptors, 71
Recombinant human tissue-type plasminogen activator, 99
Red blood cells, 277
Remikiren, 177P
Remoxipride, 149P
Renal artery stenosis, 271
Renal effects, 501P
Renal failure, 164P
Renal function, 142P, 178P, 186
Renin, 19
Renin inhibitor, 177P, 547
Repeatability, 383
Review, 1
Rheumatoid arthritis, 186
Ro 19-6327, 151P
Ro 41-1049, 151P
Ro 42-5892, 177P

S12363, 165P
SK&F 96067, 175P
Saccade velocity, 61
Saccadic eye movements, 109
Salbutamol, 496P
Saliva concentrations, 000P
*Salvia miltiorrhiza*, 147P
Schizophrenia, 490P, 491P, 495P, 505P
Shear stress, 437
Side effects, 181P
Simvastatin, 474
Skin blood flow, 172P
Smoking, 610
Smooth muscle, 303
Sodium excretion, 19
Sorbitol clearance, 427
Sparteine, 105
Spatio-temporal contrast sensitivity, 117
Species differences, 164P
Spiradoline, 143P
Spironolactone betacyclodextrin, 488P
Standard metered dose inhaler, 443, 496P
Steady-state, 78
Stereoselective, 357
Stereoselectivity, 186
Sulphotransferase, 593
Sulpiride, 149P
Sympathetic nervous system activity man, 25
Systematic review, 507
Systemic absorption, 443
Systemic availability, 136, 211
Systemic blood pressure, 45
Systemic sclerosis, 45, 489P

Tacrine, 145P
Tetracycline, 497P
Tetrodotoxin, 480
The Lilly Lecture, 13
Theophylline, 195, 497P
Therapeutic drug monitoring, 181P
Thermal clearance probe, 172P
Thermospray mass spectrometry, 163P
Thromboxane $A_2$, 271
Thromboxane $B_2$, 186
Ticarcillin, 372
Tipredane, 155P
Tobramycin, 372
Tolbutamide hydroxylase, 143P
Tolerability, 175P, 501P
Tolerance, 71
Total peripheral resistance, 331
Toxicity, 31, 149P, 166P
Transdermal, 221
Tranylcypromine, 363
Triprolidine, 67
Turbuhaler, 211

U-62,066E, 143P
Uncomplicated *Plasmodium falciparum*, 585
Undergraduate, 511
Upper gastrointestinal transit, 169P
Utilization, 579

Valproic acid, 366
Variants, 241
Vasoconstrictor, 140
Vasodilation, 45
Vasodilator, 539
Vegetarians, 148
*R*-verapamil, 93

Yohimbine, 25

Zidovudine, 128, 146P, 160P, 161P
Zidovudine pharmacokinetics, 82
Zolpidem, 61